Mary Bird Perkins Cancer Center - Comprehensive Analysis Report

Summary

Mary Bird Perkins Cancer Center is Louisiana's prominent cancer care organization, dedicated to improving survivability and lessening the burden of cancer through expert treatment, compassionate care, early detection, research, and education. The center is committed to providing world-class oncology services, delivered by a team focused entirely on cancer care. It serves communities across Louisiana and southwest Mississippi. For over 50 years, Mary Bird Perkins Cancer Center has delivered advanced cancer care and aims to detect cancer in its earliest stages, which is essential to effective treatment and long-term survivorship.

1. Strategic Focus & Objectives

Core Objectives

The core objectives of Mary Bird Perkins Cancer Center revolve around providing comprehensive, patient-focused cancer care, expanding access to leading-edge treatments, and pioneering innovative programs. The organization emphasizes high-quality, multidisciplinary care, integrating state-of-the-art treatments with compassionate patient support. Key objectives include enhancing services through strategic partnerships, expanding its geographic footprint, and leveraging advanced technologies. Specific goals include:

Reducing Louisiana's High Cancer Mortality Rate: By providing no-cost cancer screenings for breast, prostate, oral cavity, skin, and colorectal cancers, especially for medically underserved populations.

Ensuring Patient Navigation: Providing 100% of participants with an abnormal finding with patient navigation to ensure adequate follow-up until resolution.

Increasing Cancer Prevention and Early Detection Education: Delivering education to residents through community outreach and mobile medical units.

Expanding Access to Advanced Therapies: Through affiliations like OneOncology and by offering national and international clinical trials.

Specialization Areas

Mary Bird Perkins Cancer Center specializes in several key areas, demonstrating its commitment to advanced oncology care:

Cellular Therapy: Including CAR-T cell therapy offered in an outpatient setting, making it the first facility in the region to do so for blood cancers.

Theranostics: Integrating diagnostics with therapeutics for personalized treatment.

Breast Surgery and Urology: Providing specialized surgical and medical care for breast, prostate, bladder, kidney, and testicular cancers.

Adaptive MRI-Guided Radiation Therapy Program: Utilizing the Elekta Unity system for precision treatment.

Early Detection and Prevention: Focused on underserved and minority populations through programs like "Prevention on the Go" (POGO), which offers free cancer screenings.

Medical Physics Program: Operating a nationally recognized program in partnership with Louisiana State University, advancing radiation oncology science.

Clinical Research Diversity: Prioritizing diversity in clinical research to ensure more personalized and equitable treatment outcomes, with minority populations making up 21% of those on active clinical trials and 18% of new enrollments in 2024.

Target Markets

The primary target markets for Mary Bird Perkins Cancer Center include communities across Louisiana and southwest Mississippi. The center specifically focuses on underserved and minority populations within these regions, recognizing the higher cancer mortality rates due to lack of access to care and delayed diagnoses. Its geographic footprint has expanded through strategic alliances with local clinics, extending its reach into central and north Louisiana.

2. Financial Overview

Funding History

As an independent, community-owned nonprofit organization, Mary Bird Perkins Cancer Center relies on a combination of endowment, grants, and operational revenue.

Endowment Investments: As of June 30, 2025, the market value of Endowment Investments and Receivables reached $33,488,277. The Mary Bird Perkins Cancer Foundation had set an ambitious vision to grow its endowment to $50 million by 2025, a goal that was achieved ahead of schedule. Brown Advisory was engaged in May 2023 to assist with the endowment and investment portfolio.

Estimated Annual Revenue: The Cancer Center's estimated annual revenue is approximately $136.3 million.

Fiscal Year 2024 Financials (ending June 30, 2024):

Total Revenues: $229,572,561
Total Expenses: $234,486,642
Total Assets: $141,086,814
Significant Grants:

United Health Foundation Grant: A three-year, $2.3 million grant, announced in October 2023, for increasing access to prostate and colorectal cancer education, screening, and support for historically underserved individuals across Louisiana. This grant supports over 4,500 free screenings and nearly 10,000 community outreach and education interventions.
Gilead Foundation Grant: In May 2025, the clinical trials program received a nearly $400,000 grant to expand nationally-recognized clinical trials, particularly focusing on increasing participation rates of underrepresented populations in breast clinical trials by 5-10% by August 2026.

3. Product Pipeline

Key Products/Services (Clinical Research & Therapeutic Innovations)

Mary Bird Perkins Cancer Center is actively involved in clinical research and pipeline development, offering both national and international clinical trials.
Non-Small Cell Lung Cancer (NSCLC) Targeted Therapy:

Description: The center was the first worldwide to enroll and treat a patient in a Phase 3 clinical trial for NSCLC, investigating a promising targeted therapy for a common mutation.
Development Stage: Phase 3 Clinical Trial (building on an active role in an earlier Phase 1 trial).
Target Market/Condition: Patients with non-small cell lung cancer, specifically those with a common mutation targeted by the therapy.
Benefits: Provides access to next-generation therapies for various cancer types and contributes to the advancement of cancer treatment.
Broad Clinical Trials Program:

Description: Offers access to next-generation therapies across various cancer types, including brain, breast, colorectal, head and neck, kidney, lung, melanoma, pancreas, and prostate studies.
Development Stage: Ongoing across multiple phases for various cancer types.
Target Market/Condition: A wide spectrum of cancer patients requiring advanced treatment options.
Benefits: Ensures access to high-quality research studies closer to home, especially for approximately 80% of Louisiana residents through a National Cancer Institute Community Oncology Research Program (NCORP) grant in collaboration with LSU Health Sciences Centers. Increases diverse representation in clinical trials.

4. Technology & Innovation

Technology Stack

Core Platforms and Technologies:

Adaptive MRI-Guided Radiation Therapy Program (Elekta Unity System): A significant investment of over $10 million, this system combines high-resolution MRI with linear accelerator (LINAC) technology and artificial intelligence. It enables real-time imaging during treatment, allowing oncologists to precisely visualize tumors and healthy tissue, and adjust treatment plans immediately for changes in patient anatomy or tumor size. Mary Bird Perkins is the first and only organization in Louisiana to offer this precision medicine technology.
GrayOS (Gray Oncology Solutions): In May 2024, Mary Bird Perkins became the first cancer care organization in the U.S. to deploy this AI and data science-driven operating system. GrayOS streamlines cancer care operations by automating appointment scheduling based on patient preferences and resource availability, and provides clinical teams with predictive analytics and dashboards to monitor operations and anticipate bottlenecks.
Deep-Learning Technology for Radiation Oncology (Vysioneer Partnership): A multi-year collaboration launched in February 2021 to develop and integrate deep-learning technology into radiation therapy. This includes tumor auto-contouring solutions for common tumor types (brain, prostate, head and neck cancers) to expedite treatment times and improve accuracy and efficiency.

Proprietary Developments:

Breath-Hold Techniques: Developed internally and now used globally within motion management equipment for breast cancer treatment. These techniques are designed to minimize damage to surrounding tissues and organs during radiation therapy.
MyPOGO Cloud-Based Database: An internal cloud-based system used for the "Prevention on the Go" (POGO) program. It allows real-time tracking of screening events and participants, enabling the team to optimize screening schedules, maximize resources, and target underserved communities more effectively.

Scientific Methodologies: The center operates a nationally recognized medical physics program in partnership with Louisiana State University and is accredited by the Commission on Medical Physics Education Programs (CAMPEP). This program advances radiation oncology science and enhances patient care through academic and clinical collaboration.

Technical Capabilities:

Real-time treatment adaptation during radiation therapy.
AI-driven operational optimization and scheduling.
Automated tumor contouring for enhanced radiation delivery.
Advanced diagnostic imaging capabilities and molecular testing to guide personalized treatments.

5. Leadership & Management

Executive Team

Jonas Fontenot, PhD, MBA

Current Position: President and CEO.
Professional Background: Previously served as Chief Operating Officer and Chief of Medical Physics.
Key Contributions: Instrumental in leading strategic partnerships and the expansion of the Cancer Center's services and footprint, including the integration with MD Clinics and the OneOncology partnership.
Jodi Conachen

Current Position: Chief Operating Officer.
Professional Background: A Zachary resident.
Key Contributions: Oversees operational aspects, emphasizing the importance of partnerships and localized, innovative care delivery, and upholding accreditation standards.

Todd Stevens

Current Position: Chief Strategic and Business Officer.
Professional Background: Previously served as President and Chief Executive Officer.
Key Contributions: Played a key role in the strategic partnership with OneOncology, emphasizing the organization's philosophy of focusing 100% on cancer care.
Daniel LaVie, M.D.

Current Position: Medical Director of Hematology and Medical Oncology.
Professional Background: Comments on the CoC accreditation.
Key Contributions: Ensures high standards in hematology and medical oncology treatment, emphasizing leading-edge care.

Sotirios Stathakis, Ph.D.

Current Position: Dr. Charles M. Smith Chief of Physics.
Professional Background: Expressed excitement about the partnership with Gray Oncology Solutions.
Key Contributions: Leads the medical physics department and drives innovation in radiation therapy, including the adoption of AI-driven solutions.
Renea Duffin

Current Position: Vice President of Cancer Support and Outreach.
Professional Background: Medical Director for the Prevention on the Go (POGO) program.
Key Contributions: Oversees critical prevention and early detection programs, leveraging data from the cloud-based database (MyPOGO) to improve community outreach and access to care for uninsured or underinsured individuals.

Victor Lin, MD, PhD

Current Position: Research Medical Director, Physician-scientist.
Professional Background: Has propelled Mary Bird Perkins' clinical research program.
Key Contributions: Drives the clinical research program, focusing on advanced Phase 1 clinical trials and promoting diversity in research participation.
Kim Hicks

Current Position: Administrator, North Louisiana, and Director of Clinical Affairs.
Professional Background: Commented on the QOPI certification.
Key Contributions: Manages clinical operations and ensures quality care standards in the North Louisiana region.

Recent Leadership Changes

Todd Stevens, formerly President and Chief Executive Officer, transitioned to Chief Strategic and Business Officer. Jonas Fontenot, PhD, MBA, previously Chief Operating Officer and Chief of Medical Physics, assumed the role of President and CEO.

6. Talent and Growth Indicators

Mary Bird Perkins Cancer Center demonstrates a robust growth trajectory and a commitment to its workforce and patient care capacity.

Employee Growth: The organization experienced an employee growth of 10% in the last year, with 378 employees as of 2024.

Patient Care Metrics (Fiscal Year ending June 30, 2024):

Serves 82,000 patients annually.
Conducts approximately 54,700 radiation oncology treatments.
Performs 36,500 medical oncology treatments.
Expansion and Recruitment: Continuous expansion of services and locations, coupled with partnerships designed to attract additional oncologists (e.g., through OneOncology), indicates ongoing recruitment efforts. The expansion into central and north Louisiana through MD Clinics will further expand the workforce.

Workforce Development: Pioneers future cancer professionals by providing educational funding for physicists in the Dr. Charles M. Smith Medical Physics Program.

7. Social Media Presence and Engagement

Digital Footprint

Mary Bird Perkins Cancer Center actively utilizes social media to communicate its mission, achievements, and engage with its community.
Brand Messaging: Emphasizes comprehensive cancer care, early detection, research, and education, often highlighting patient stories and community impact.

Community Engagement: Regularly communicates updates on events, screenings, and health education initiatives.

Public Awareness Campaigns: Uses its media channels to highlight the process of a large-scale mural in North Baton Rouge, designed to amplify public understanding of clinical trials and spark conversations about representation in clinical research.

Patient Support Initiatives: Launched the "Helping Hands" online registry in 2020, a digital platform allowing patients to create a wish list of non-medical tasks for friends and family, providing essential patient support.

8. Recognition and Awards

Industry Recognition

Mary Bird Perkins Cancer Center has received numerous recognitions, demonstrating its commitment to quality and innovation in cancer care.
Commission on Cancer (CoC) Accreditation: Awarded a three-year accreditation by the American College of Surgeons' Commission on Cancer, recognizing comprehensive, high-quality, and multidisciplinary patient-centered cancer care across its locations in southwest Louisiana and Natchez, MS. This gold standard accreditation involves meeting rigorous quality care standards and a triennial evaluation process.

American College of Radiology (ACR) Reaccreditation: Achieved a three-year term of reaccreditation in radiation oncology for multiple locations (Baton Rouge, Gonzales, Hammond, Covington, Houma) and in nuclear medicine for Gonzales and Covington. The ACR gold seal signifies the highest level of quality and patient safety.

Commission on Medical Physics Education Programs (CAMPEP) Reaccreditation: The Medical Physics Residency Program holds full reaccreditation, making Mary Bird Perkins the first center in Louisiana to establish such a program.

Association of Community Cancer Centers (ACCC) Innovator Award: Recognized with an Innovator Award for its early detection program, acknowledging its forward-thinking solutions for effective cancer care delivery, particularly for uninsured and underinsured adults.

Quality Oncology Practice Initiative (QOPI) Certification: Its North Louisiana locations are certified by the QOPI Certification Program, indicating adherence to rigorous, nationally recognized benchmarks for quality outpatient hematology-oncology care.

Lung Cancer Alliance Screening Center of Excellence: Designated as a Screening Center of Excellence by the Lung Cancer Alliance for its Covington location.

Internal Awards: Annually presents prestigious awards like the Hillar C. Moore, Jr., Memorial Outstanding Leadership Award, the Louis D. Curet Memorial Volunteer Fundraiser Award, and the D. Jensen Holliday Memorial Community Service Award to individuals and organizations for their philanthropic and service contributions to the fight against cancer.

9. Competitive Analysis

Major Competitors

Mary Bird Perkins Cancer Center operates within a competitive environment, with several other organizations contributing to the cancer care landscape. Key competitors include:
OneOncology

Company Overview: A national platform for independent oncology practices.
Focus Areas: Enhancing community-based cancer care through group purchasing, operational optimization, practice growth, and clinical innovation. While a competitor, Mary Bird Perkins has also strategically affiliated with OneOncology to leverage its resources and expand services.
Technological Capabilities: Provides integrated platforms for support across HR, finance, marketing, business development, EMR setup (e.g., with Flatiron Health), and advanced clinical services